Intraday chart awaiting data
Daily+0.89%Oct 26 · 3:00 PM CT
Year to date (TR)+4.75%as of October 26, 2026
NOT JUST ANOTHER INDEX. IT'S THE NEW GENERATION®
Think IPO. Think IPOX®.
Specialized solutions for investors seeking exposure to the companies shaping what comes next.
THE IPOX® INDEXES
Intraday chart awaiting data
Daily+1.15%Oct 26 · 3:00 PM CT
Year to date (TR)+1.81%as of October 26, 2026
IPXI
IPOX® International Index
Tracked byFirst Trust International Equity Opportunities ETF FPXI ETF ↗
Intraday chart awaiting data
Daily-0.30%Oct 26 · 3:00 PM CT
Year to date (TR)+6.66%as of October 26, 2026
IPOX® SCHUSTERINDEXES · RESEARCH · NEW LISTINGSEST. 2004
THE GLOBAL PIPELINE
Upcoming listings
Expected
MSGR US
United States · NYSEExpected
MSG Rangers
Professional hockey
Spin-Off
Valuation
USD 2.50 billion
NYSEMSGR US
Expected
MSGK US
United States · NYSEExpected
MSG Knicks
Professional basketball
Spin-Off parent
Valuation
USD 7.50 billion
NYSEMSGK US
Priced
MIM SP
Singapore · Singapore ExchangePriced
Mi Material Holding
Semiconductor materials
Offer sizeUSD 109.05 millionSGD 139.49 million
Singapore ExchangeMIM SP
Expected
Germany · Deutsche BörseExpected
Tk Accelis Group
Materials distribution
Spin-Off
Valuation
USD 4.03 billion
EUR 3.60 billion
Deutsche Börse
Expected
2384 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Suzhou Dongshan Precision Manufacturing
Electronic components
Offer sizeUSD 1.36 billionHKD 10.67 billion
Hong Kong Stock Exchange2384 HK
Expected
3275 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Microintelligence
Industrial robotics
Offer sizeUSD 90.54 millionHKD 709.92 million
Hong Kong Stock Exchange3275 HK
Priced
0053F0 KS
South Korea · Korea Exchange (KOSDAQ)Priced
TNE Korea
Industrial turbomachinery
Offer sizeUSD 27.76 millionKRW 36.72 billion
Korea Exchange (KOSDAQ)0053F0 KS
Expected
652A JP
Japan · Tokyo Stock ExchangeExpected
Toggle Holdings
Real Estate
Offer sizeUSD 85.89 millionJPY 13.60 billion
Tokyo Stock Exchange652A JP
Priced
359410 KS
South Korea · Korea Exchange (KOSDAQ)Priced
Youngkwang
Ship and plant equipment
Offer sizeUSD 28.99 millionKRW 38.42 billion
Korea Exchange (KOSDAQ)359410 KS
Priced
0147B0 KS
South Korea · Korea Exchange (KOSDAQ)Priced
Lablup
AI infrastructure software
Offer sizeUSD 31.31 millionKRW 41.42 billion
Korea Exchange (KOSDAQ)0147B0 KS
Expected
656A JP
Japan · Tokyo Stock ExchangeExpected
Allganize Holdings
Information & Communication
Offer sizeUSD 28.92 millionJPY 4.53 billion
Tokyo Stock Exchange656A JP
Expected
658A JP
Japan · Tokyo Stock ExchangeExpected
Estie
Real estate data
Offer sizeUSD 38.48 millionJPY 6.09 billion
Tokyo Stock Exchange658A JP
Expected
United Arab Emirates · Dubai Financial MarketExpected
DIP Holding
Mixed-use real estate
Offer sizeUSD 566.93 millionAED 2.08 billion IPOX® Estimate
Dubai Financial Market
Expected
0162D0 KS
South Korea · Korea Exchange (KOSDAQ)Expected
Dongwon Parts
Semiconductor equipment parts
Offer sizeUSD 37.98 millionKRW 50.24 billion
Korea Exchange (KOSDAQ)0162D0 KS
14 upcoming listings
RESEARCH & INSIGHT
All newsletters +Our newsletters
LATEST FROM IPOX®
All news +News
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Discusses Biotech IPO Activity
Reuters featured IPOX® Associate Lukas Muehlbauer in its coverage of US IPO roadshows launched by Aspen Neuroscience and Bambusa Therapeutics. Muehlbauer explained that clinical catalysts can attract specialist investors despite economic uncertainty and higher interest rates. He noted that strong recent debuts could encourage further biotech listings, while emphasizing that investor appetite remains selective as financing costs challenge companies that may still be years away from generating their first revenues.
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Discusses Anthropic’s IPO and AI Valuations
Reuters featured IPOX® Associate Lukas Muehlbauer in two articles examining Anthropic’s IPO filing and its implications for AI investment. Industry professionals highlighted the offering as a test of investor confidence amid concerns over valuations, spending and profitability. Muehlbauer said the IPO would establish a benchmark for valuing leading AI labs, while emphasizing that investors would distinguish between proven customer demand and spending based on anticipated growth.
Media mentions · Reuters
Reuters: IPOX® VP Kat Liu Comments on Iambic Therapeutics’ AI Drug Discovery Platform and IPO Valuation
Nvidia-backed Iambic Therapeutics is seeking to raise up to $159.4 million in its U.S. IPO, targeting a valuation of up to $805.8 million. IPOX® Vice President Kat Liu told Reuters that Iambic’s value depends primarily on its drug pipeline and prospects for approval and commercialization. The company uses AI to develop cancer treatments and plans to list on Nasdaq as “IAM,” as biotech attracts investor interest despite rising Treasury yields, market volatility, and geopolitical tensions affecting the broader IPO market.
Media mentions · Fortune
Fortune: IPOX® VP Kat Liu Comments on Oura’s Postponed IPO and Valuation Questions
IPOX® VP Kat Liu was interviewed for Fortune on Oura’s decision to postpone its IPO, offering perspective on valuation concerns, deal structure, and investor expectations. Liu discussed how Oura’s positioning as either a digital-health platform or consumer hardware company could shape valuation views, while also noting the market signal created by a high proportion of secondary shares.
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Airtel Money’s London IPO
Reuters reports that Airtel Money is targeting a valuation of approximately $7 billion in its London IPO, which could become the city’s largest offering since September 2025. IPOX® Associate Lukas Muehlbauer said the deal demonstrates London’s ability to attract sizable international listings while also reflecting a buyer’s market. He noted that companies must remain realistic about valuation as Airtel Money prepares to raise about $703 million through the sale of 270 million shares ahead of its October debut.
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Oura IPO Delay and Market Conditions
Reuters reports that Oura postponed its planned U.S. IPO as market volatility and higher interest rates increased investor caution toward new listings. IPOX® Associate Lukas Muehlbauer commented that higher rates are making investors more selective, particularly on growth valuations, while noting that the IPO window remains open. He also highlighted reported demand for Oura’s offering, which was said to be around four times oversubscribed, and pointed to Anthropic’s planned IPO as an important upcoming market test.
OUR SERVICE OFFERINGSA world of new listings.
A world of new listings.
A disciplined approach.
New listings reflect economic growth and innovation. Our services bring a disciplined approach to this evolving global universe through independent research, index licensing, portfolio management and tailored investment solutions.
Explore our services